IOD: Revenue up 16.9% and net loss down 12.9%, but going concern risk persists
IOD: FY2026 saw double-digit revenue growth, improved margins, and a strong UK-led platform for FY2027
Shaw and Partners Keeps Their Buy Rating on IODM Ltd. (IOD)
IODM Issues 1 Million Unquoted Convertible Notes in New Security Class
Idorsia welcomes Amer Joseph as new Chief Medical Officer and Head of Global Clinical Development
IODM seals 283‑university U.S. platform deal to fast-track North American growth